Levonadifloxacin|154357-42-3|-陌孚医药/Medlife

您当前的位置：

Levonadifloxacin

目录号: PL12031 纯度: ≥99%

Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) 是一种广谱的抗葡萄球菌剂。Levonadifloxacin 对甲氧西林敏感的金黄色葡萄球菌 (MSSA) 和对甲氧西林耐药的金黄色葡萄球菌具有抗菌活性，减少单核细胞 THP-1 吞噬的 MRSA 和 MSSA 菌株。

CAS No. :154357-42-3

商品编号	规格	价格	会员价
PL12031-5mg	5mg	¥4018.00	请登录
PL12031-10mg	10mg	¥6107.00	请登录
PL12031-25mg	25mg	¥12054.00	请登录
PL12031-50mg	50mg	¥19287.00	请登录
PL12031-100mg	100mg	询价	询价
PL12031-200mg	200mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Levonadifloxacin
中文别名	左氧那地沙星
英文名称	Levonadifloxacin
英文别名	1H,5H-Benzo[ij]quinolizine-2-carboxylicacid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5S)-;1H,5H-Benzo[ij]quinolizine-2-carboxylicacid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-...;LEVONADIFLOXACIN;(-)-nadifloxacin;(S)-(-)-9-fluoro-8-(4-hydroxy-1-piperidyl)-5-methyl-6,7-dihydro-1-oxo-1H,5H-benzo[ij]quin;(S)-(-)-nadifloxacin;AG-E-02241;CTK0H0569;Levonadifloxacin [INN];S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid;SureCN36594;(S)-9-Fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid;(S)-(-)-OPC-7251;JYJTVFIEFKZWCJ-JTQLQIEISA-N;(4S)-1-Oxo-4β-methyl-5,6-dihydro-7-(4-hydroxypiperidino)-8-fluoro-4H-3a-aza-1H-phenalene-2-carboxylic acid;(5S)-9-Fluoro-6,7-dihydro-8-(4-hydroxypiperidino)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid;1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (S)-;1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5S)- (9CI)
Cas No.	154357-42-3
分子式	C₁₉H₂₁N₂O₄F
分子量	360.38
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

生物活性

Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes.

性状

Solid

体外研究(In Vitro)

Levonadifloxacin (32 μg/mL; 24 h) achieves a 90-99%?intracellular reduction of MSSA and MRSA strains phagocytized in THP-1 monocytes with MICs of 0.03 μg/mL and 15.0 ng/mL.
has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Levonadifloxacin (12.5-400 mg/kg; s.c.; single dose) shows efficacy in vivo against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model.
has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Dubois J, et al. Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations. J Med Microbiol. 2019 Dec;68(12):1716-1722.
[2]. Bhagwat SS, et al. In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00909-19.

溶解度数据	In Vitro: DMSO : 125 mg/mL (346.86 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation